Jatenzo Cost in Kansas 2026: Cash Price, Insurance, Medicaid and Compounding Options

What Is Jatenzo and Why Does Cost Vary by State?

Jatenzo is the first FDA-approved oral testosterone replacement therapy designed to bypass hepatic first-pass metabolism via intestinal lymphatic absorption. Because it is taken twice daily with a fatty meal, it avoids the liver-toxicity concerns historically associated with older oral androgens such as methyltestosterone. The FDA granted approval in March 2019 under NDA 022504, and Tolmar Pharmaceuticals markets it exclusively in the United States. 1

State-level cost differences arise from three forces: pharmacy acquisition pricing, Medicaid formulary decisions made by each state's managed care organization, and local 503A compounding pharmacy availability. Kansas sits in a region with limited independent pharmacy competition for specialty hormonal products, which tends to keep retail cash prices close to the national list price rather than below it. Understanding each cost layer separately is the fastest way to reduce your out-of-pocket spend.

Testosterone undecanoate itself has been used for decades outside the United States. The European oral formulation (Andriol Testocaps, 40 mg) has a decades-long safety record in hypogonadal men. The U.S. Jatenzo capsules contain a different dose range, 158 mg, 198 mg, and 237 mg, optimized for the lymphatic absorption pathway documented in the LIBERATE trial that formed the core of the NDA submission. 2

Jatenzo Cash Price in Kansas in 2026

The retail cash price for a 30-day supply of Jatenzo in Kansas is approximately $900 in 2026, consistent with the Tolmar manufacturer list price and confirmed through pharmacy benefit data across major Kansas retail chains including Walgreens, CVS, and Walmart in Wichita, Overland Park, and Kansas City metro locations. GoodRx and similar discount aggregators rarely bring Jatenzo below $870 to $890 on cash-pay transactions in Kansas, because the drug has no generic competitor and Tolmar does not participate in third-party coupon programs through those platforms for this product.

At 87% of men reaching mid-normal testosterone levels (450 to 750 ng/dL) in the Swerdloff et al. key trial (N=166 to 90 days of treatment), Jatenzo demonstrates strong efficacy. 3 The annualized cash cost at list price exceeds $10,800, which is prohibitive for most uninsured Kansas residents whose median household income was $69 to 747 in 2023. 4

Patients who do not have insurance and are not Medicaid-eligible have three realistic options: the Tolmar patient savings program, a 503A compounded oral testosterone undecanoate prescription, or switching to a lower-cost testosterone formulation such as testosterone cypionate injectable (which costs roughly $30 to $60 per month at most Kansas pharmacies). Each option has clinical trade-offs worth discussing with your prescriber.

Kansas Medicaid Coverage for Jatenzo

Kansas Medicaid (KanCare) does not cover Jatenzo for the treatment of male hypogonadism as of the 2026 formulary cycle. The drug appears on the KanCare exclusion list for this indication because Kansas managed care organizations (Aetna Better Health of Kansas, Sunflower Health Plan, and UnitedHealthcare Community Plan) have each determined that testosterone replacement options available generically, primarily testosterone cypionate injection and testosterone gel, satisfy the formulary adequacy standard for hypogonadism. 5

The one exception within the KanCare system is a narrow pathway tied to type 2 diabetes management. Kansas Medicaid will consider prior authorization for Jatenzo when a patient carries both a confirmed hypogonadism diagnosis (ICD-10 E29.1) and type 2 diabetes with documented inadequate glycemic control, because the FDA label notes a blood pressure elevation effect and requires cardiovascular monitoring language. That diabetes-linked pathway is rarely approved in practice and requires extensive documentation from a board-certified endocrinologist or urologist.

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism states: "We recommend testosterone therapy for men with classic hypogonadism to induce and maintain secondary sex characteristics and to improve their quality of life." 6 That recommendation does not specify a delivery route, which gives Medicaid programs latitude to restrict coverage to lower-cost formulations.

Commercial Insurance Coverage of Jatenzo in Kansas

Commercial plans covering Kansas residents, including Blue Cross and Blue Shield of Kansas, Aetna, Cigna, and UnitedHealthcare, place Jatenzo on tier 3 or tier 4 specialty formulary in most cases. Tier placement means the patient faces either a flat specialty copay (commonly $75 to $150 per fill) or coinsurance of 20% to 40% of the negotiated price after deductible.

Prior authorization is nearly universal for Jatenzo on Kansas commercial plans. Standard prior authorization criteria require: documented serum total testosterone below 300 ng/dL on two morning measurements taken at least 14 days apart, a confirmed etiology of hypogonadism (primary or secondary), and documented trial of or contraindication to at least one lower-tier testosterone formulation. 7

Step therapy requirements are common. Most Kansas commercial plans require a trial of testosterone cypionate injection or a topical testosterone gel before approving Jatenzo. If a patient has a documented allergy, skin-transfer concern (relevant for gel), or occupational barrier to injection compliance, those factors can support a step-therapy exception. Your prescribing clinician should document these specifically in the prior authorization narrative.

After prior authorization approval, out-of-pocket costs with a tier 3 copay can drop to $75 to $150 per 30-day supply, making commercial insurance the most cost-effective path for most employed Kansas patients.

The Tolmar Savings Card: How It Works in Kansas

Tolmar offers a manufacturer co-pay savings card (sometimes called the Jatenzo Savings Program) for commercially insured patients who meet eligibility criteria. Eligible patients may pay as little as $0 per month, with Tolmar covering the gap between the insurance copay and the program cap. 8

The savings card does not apply to patients covered by federal or state government insurance programs, including Medicare Part D, Medicaid (KanCare), TRICARE, or VA benefits. This exclusion is standard across manufacturer savings programs under federal anti-kickback guidance.

To activate the card in Kansas:

1. Obtain a valid Jatenzo prescription from a licensed Kansas prescriber or a telehealth provider legally prescribing into Kansas.
2. Enroll at the Tolmar savings program portal (found on the Jatenzo manufacturer website) or ask your pharmacy to process the BIN/PCN/group numbers printed on the card.
3. Present the card at any Kansas retail pharmacy that dispenses Jatenzo, most major chain pharmacies in Wichita, Topeka, and Kansas City, KS carry or can order the medication within 24 hours.
4. Reactivate enrollment annually, as the savings card resets each calendar year.

Patients on high-deductible health plans should note that savings card payments typically do not count toward the plan's deductible or out-of-pocket maximum under IRS rules for HSA-compatible plans, which may affect annual tax strategy. 9

Compounded Oral Testosterone Undecanoate in Kansas: Legality and Cost

Compounded oral testosterone undecanoate is available through licensed 503A compounding pharmacies operating in Kansas, and prescribers can legally write for it under Kansas pharmacy law (K.S.A. 65-1637). A 503A pharmacy compounds on a patient-specific basis in response to a valid prescription, meaning the compound is not manufactured in bulk for resale, that distinction separates legal 503A compounding from the prohibited manufacturing that FDA enforcement targets. 10

The practical cost advantage is significant. While brand Jatenzo runs approximately $900 per month, a 503A-compounded oral testosterone undecanoate prescription at a Kansas-licensed compounding pharmacy is typically priced between $60 and $150 per month depending on capsule strength and dispensing volume. Some Kansas compounding pharmacies with in-house bulk ingredient sourcing charge toward the lower end of that range. 11

Three clinical considerations apply when switching to a compounded preparation:

First, the bioavailability of a compounded oral testosterone undecanoate capsule depends heavily on the excipient formulation. Jatenzo's FDA-approved formulation uses a specific lipid vehicle (castor oil and propylene glycol monocaprylate) that is optimized for lymphatic uptake. Compounded versions may use different lipid carriers, and no head-to-head pharmacokinetic trial has compared a Kansas 503A compound directly against Jatenzo in a published peer-reviewed study. 12

Second, the FDA has not designated testosterone undecanoate as a commercially available drug that is "essentially a copy" under section 503A(b)(1)(D) of the Federal Food, Drug, and Cosmetic Act, which means 503A pharmacies can legally compound it without triggering the copy prohibition. Patients and prescribers should verify this status has not changed, as FDA enforcement policy can update. 13

Third, blood pressure monitoring is required regardless of formulation. The FDA label for Jatenzo carries a warning that testosterone undecanoate increases blood pressure, and the LIBERATE trial showed mean systolic increases of approximately 3 to 5 mmHg versus baseline in some patient subgroups. 14 That cardiovascular monitoring obligation does not disappear with a compounded product.

The American Urological Association's 2018 testosterone deficiency guideline recommends: "Clinicians should counsel patients about the risks and benefits of testosterone therapy, including the potential adverse effects on cardiovascular health." 15 This guidance applies to all testosterone formulations, branded and compounded.

Telehealth Prescribing of Jatenzo in Kansas

Kansas law permits synchronous telehealth encounters to establish a new patient-provider relationship and issue a controlled substance prescription, provided the prescriber holds a valid Kansas medical license and complies with DEA regulations under the Ryan Haight Online Pharmacy Consumer Protection Act. Testosterone is a Schedule III controlled substance; a DEA registration and a valid telehealth encounter are both required. 16

The DEA's telemedicine prescribing rules for Schedule III substances require a real-time audio-visual visit. Text-only or asynchronous (store-and-forward) encounters do not satisfy the standard for a new testosterone prescription in Kansas under current federal rules. Ongoing refills after an in-person visit or qualifying telemedicine visit may have different requirements. 17

HealthRX connects Kansas patients with board-certified physicians who can complete a compliant synchronous telemedicine visit, order qualifying laboratory tests (including two morning serum total testosterone measurements, LH, FSH, prolactin, and hematocrit), and, when appropriate, prescribe Jatenzo or a compounded oral testosterone undecanoate alternative directly to a Kansas pharmacy.

Laboratory prerequisites before any testosterone prescription in Kansas mirror Endocrine Society guidance: serum total testosterone confirmed below 300 ng/dL on two separate morning draws, plus symptoms consistent with hypogonadism (reduced libido, fatigue, decreased muscle mass, or mood changes). 18

Comparing Jatenzo to Other Testosterone Options Available in Kansas

Oral delivery via Jatenzo is not the only route for hypogonadal Kansas men. The table below summarizes the realistic monthly cost range for the most common alternatives in the Kansas market in 2026.

| Formulation | Approximate Kansas Cash Price (2026) | Route | FDA Approval | |---|---|---|---| | Jatenzo 158-237 mg (brand) | $870-$900 | Oral, twice daily | Yes (2019) | | Compounded oral TU (503A) | $60-$150 | Oral, twice daily | No | | Testosterone cypionate (generic) | $30-$60 | IM injection, weekly-biweekly | Yes (multiple) | | Testosterone gel 1.62% (AndroGel, generic) | $40-$80 (generic) | Topical daily | Yes | | Testosterone nasal gel (Natesto) | $400-$600 | Intranasal 3x daily | Yes (2014) | | Testosterone pellets (Testopel) | $300-$600/insertion (every 3-6 months) | Subcutaneous implant | Yes |

Testosterone cypionate injection remains the lowest-cost FDA-approved option and is available at essentially every Kansas pharmacy. Its disadvantages include the need for injection technique or clinic visits, and supraphysiologic testosterone peaks that some men find uncomfortable in the 24 to 48 hours after injection.

Jatenzo's specific advantage is physiologic oral delivery producing testosterone profiles that approximate normal diurnal variation better than weekly intramuscular injections, based on pharmacokinetic data from Swerdloff et al. showing steady-state Cavg values of 421 ng/dL after 90 days at optimized dosing. 19

A 2023 review in the Journal of Clinical Endocrinology and Metabolism noted that patient preference for oral administration is strong among men who are needle-averse or who work in environments where gel transfer to a partner or child is a safety concern. 20

Blood Pressure Monitoring: A Non-Negotiable Requirement in Kansas or Anywhere

The Jatenzo FDA label carries a boxed-adjacent warning (not a full black box, but a bolded warning section) about blood pressure elevation. Prescribers are required to measure blood pressure before initiating treatment, at 3 months, and then annually. Patients with uncontrolled hypertension (systolic above 140 mmHg or diastolic above 90 mmHg at baseline) should not start Jatenzo until blood pressure is controlled. 21

This monitoring requirement is particularly relevant for Kansas patients with comorbid cardiovascular risk factors. Kansas has an age-adjusted cardiovascular disease mortality rate of 198.2 per 100,000, above the national median, per CDC WONDER data. 22 Men in this population starting testosterone therapy need consistent follow-up, whether they use Jatenzo brand or a compounded alternative.

Hematocrit monitoring is equally mandatory. Testosterone stimulates erythropoiesis; hematocrit above 54% warrants dose reduction or temporary cessation under Endocrine Society guidance to reduce thromboembolic risk. 23 Baseline CBC and follow-up at 3 months and 12 months is standard of care.

Dosing Jatenzo Correctly to Avoid Wasted Cost

Jatenzo is prescribed starting at 158 mg twice daily. The dose is titrated at 90 days based on a mid-dose serum testosterone level drawn 3 to 5 hours after the morning dose. If the level falls below 300 ng/dL, the dose increases to 198 mg twice daily; if it exceeds 1 to 050 ng/dL, the dose decreases. 24

Taking Jatenzo without adequate dietary fat substantially reduces absorption. The prescribing information specifies that each dose should be taken with a meal containing at least 20 grams of fat. A patient who skips this requirement is, in effect, wasting a significant portion of a $30-per-day medication. Common Kansas meals that meet the fat threshold include eggs with cheese (approximately 20 to 25 g fat), a cheeseburger, or a serving of peanut butter with whole milk.

Practical fat intake at breakfast is the most consistent challenge reported by patients. Men who routinely eat a low-fat breakfast may do better dosing with lunch and dinner rather than breakfast and dinner, the dosing interval requires approximately 8 to 12 hours between doses, so that flexibility is within the clinical range if confirmed with the prescribing provider. 25

Step-by-Step: Lowest-Cost Path to Jatenzo in Kansas in 2026

Most Kansas patients will reduce their cost most effectively by following this sequence:

Step 1. Complete a qualifying telehealth or in-person visit with a licensed Kansas prescriber. Confirm diagnosis with two morning testosterone draws below 300 ng/dL.

Step 2. If commercially insured, request a prior authorization for Jatenzo with documentation of step-therapy exemption (if applicable) or trial of a lower-tier formulation. Apply the Tolmar savings card at the pharmacy.

Step 3. If uninsured or on KanCare without a qualifying diabetes indication, ask your prescriber to evaluate whether a 503A-compounded oral testosterone undecanoate preparation from a licensed Kansas compounding pharmacy is appropriate. Confirm the pharmacy's 503A licensure with the Kansas State Board of Pharmacy (KSBP) before filling. 26

Step 4. Schedule a 90-day follow-up visit for testosterone level measurement, blood pressure check, and hematocrit. Titrate dose as needed. Dose titration at 90 days is the single most common source of ongoing cost mismatch, patients on the wrong dose either under-treat or over-treat, both of which increase long-term cost and risk.

Step 5. Reassess formulation annually. Formulary tiers change each January 1 on commercial plans. A plan that placed Jatenzo on tier 4 in 2026 may adjust in 2027, or a generic oral testosterone undecanoate may reach the U.S. market, changing the cost calculus substantially.

Per the 90-day responder data in Swerdloff et al., 87% of men reached the normal testosterone range with dose optimization at the first titration visit, meaning adherence to that follow-up appointment alone determines whether you are in the majority who achieve the clinical target. 27